Veracyte, Inc.

Veracyte, Inc., a South San Francisco-based medical diagnostic company, operates as a prime contractor delivering proprietary molecular genomic testing services to federal healthcare agencies through delivery orders and single-award indefinite-delivery contracts, competing predominantly on a full-and-open basis with no small business set-asides. The company is a for-profit corporate entity with a subsidiary, Veracyte Labs SD Corporation, and specializes in advanced gene expression analysis for precision medicine applications across the VA healthcare system, Defense Health Agency, and Indian Health Service.

Veracyte's federal capability portfolio centers on three named proprietary diagnostic classifiers: the Afirma Genomic Sequencing Classifier for thyroid nodule malignancy risk assessment, the Decipher Prostate Cancer Test for metastatic potential evaluation, and reference laboratory services including specialty genomic testing. Representative work includes a $1.85 million firm fixed-price delivery order from Veterans Integrated Service Network 17 for thyroid molecular genomic testing through July 2028, a $697,200 purchase order from VISN 7 for Afirma testing and expression atlas services through January 2028, a $656,900 delivery order from the Indian Health Service for molecular thyroid nodule testing services through September 2030, and a $593,716 definitive contract from VISN 8 for specialty genomic laboratory testing through July 2026. Recent 2026 awards include a $412,750 single-award IDIQ from VISN 5 for molecular testing services through March 2031 and a $890,640 single-award IDIQ from VISN 16 for thyroid testing services through September 2029.

Customer concentration is heavily weighted to the VA healthcare system. The top five customer networks account for 75% of awards by count and 76% of combined potential value. VISN 23 dominates both rankings with 33 awards worth $4.6 million combined potential value, followed by VISN 8 (17 awards, $2.6 million), VISN 5 (14 awards, $872 thousand), and VISN 16 (9 awards, $2.3 million). A critical outlier in the dollars ranking is the Department of the Navy Bureau of Medicine and Surgery, which places only 4 awards but anchors $6.5 million in combined potential value — a concentration shift reflecting a handful of high-dollar contracts with military healthcare beneficiaries. VISN 17 and VISN 12 each hold single large awards worth $2.3 million. The company has served 18 distinct federal agencies in recent contract activity.

Veracyte holds three primary vehicle positions. The GSA Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II) supports 12 task orders worth $4 million in combined potential value, operating as the master contract under which delivery orders flow to multiple VISNs and the Defense Health Agency. Three single-award indefinite-delivery contracts dominate the IDIQ footprint: the $2 million VISN 23 Reference Laboratory Services IDIQ (May 1, 2023 through April 30, 2028) with 18 task orders worth $1.2 million, the $890,640 VISN 16 Thyroid Testing IDIQ (October 1, 2024 through September 30, 2029) with 4 delivery orders issued as of October 2025, and the $412,750 VISN 5 Molecular Testing Services IDIQ (March 23, 2026 through March 22, 2031). An older $600,000 VISN 23 Reference Laboratory Services IDIQ running through April 2028 continues to generate task orders.

Activity has remained relatively flat year over year across the trailing five years, averaging 9 awards annually (2022: 6, 2023: 11, 2024: 9, 2025: 9, 2026: 10 as of mid-July). Nine awards with ultimate completion dates in the next twenty-four months carry combined potential value of $1.9 million, representing moderate recompete exposure. Combined potential value across all 106 prime awards totals $23.9 million, with $6.5 million obligated (27% of ceiling), indicating significant contract headroom and sustained cash flow through 2029-2031 completions. The vendor operates exclusively as a prime contractor with no subcontract activity in the federal footprint, positioning Veracyte as a direct service provider rather than a sub-tier participant. Categorization is heavily concentrated in NAICS 621511 (Medical Laboratories), accounting for 98 of 106 awards, and PSC Q301 (Reference Laboratory Testing) for 85 awards, reflecting the company's specialized diagnostic focus.